Category 3 abuse-deterrent study of the abuse-deterrent, extended-release oxycocone product Egalet 002.

Trial Profile

Category 3 abuse-deterrent study of the abuse-deterrent, extended-release oxycocone product Egalet 002.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Dec 2016 According to an Egalet media release, full data from this trial will be presented at a medical meeting in 2017.
    • 16 Dec 2016 Results published in an Egalet Media Release
    • 25 Aug 2016 According to an Egalet media release, the data of this trial would be presented PAINWeek 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top